From Platform to Patient Impact
RBL Ventures partners with scientific founders, leading physicians, and world-class researchers to transform breakthrough discoveries into medicines that improve patients’ lives.
Located within the Texas Medical Center ecosystem, RBL Ventures combines access to exceptional scientific innovation with the operational expertise, infrastructure, and strategic partnerships required to build successful biotechnology companies.
We work alongside founders from the earliest stages of company creation, helping bridge the gap between breakthrough science and meaningful patient impact.
$4.6B In Academic R&D
Only a fraction generates commercial biotech value
Texas is home to one of the largest concentrations of biomedical research, clinical expertise, and healthcare innovation in the world. Yet many promising discoveries never advance beyond the laboratory.
Located at TMC Helix Park in the heart of the Texas Medical Center, RBL Ventures operates within a uniquely connected ecosystem where researchers, clinicians, entrepreneurs, and investors collaborate to accelerate innovation.
With access to institutions including MD Anderson Cancer Center, Baylor College of Medicine, UTHealth Houston, Texas A&M University, and Rice University, founders gain early clinical insight, stronger translational feedback, and closer alignment with real-world patient needs.
Latest News
Advancing a Portfolio of High-Impact Companies
RBL Ventures partners alongside founders to transform scientific discoveries into focused, execution-ready biotechnology companies
Our model is built on long-term alignment, shared commitment, and active engagement throughout the company-building process. We help assemble the expertise, resources, and partnerships necessary to advance promising innovations toward meaningful development milestones.
Today, this approach is reflected in a growing portfolio of companies, including Sentinel BioTherapeutics, Steer Biotherapeutics, and Duracyte, each pursuing innovative approaches to address significant unmet patient needs.
Portfolio Highlights
Latest companies to emerge from stealth
Sentinel BioTherapeutics is advancing encapsulated protein producers (ePPs) that drive in vivo expansion of tumor-infiltrating lymphocytes (TILs) to treat patients with metastatic cancer in the peritoneal cavity.
SteerBio is advancing a first-in-class regenerative therapy aimed at repairing the lymphatic system and treating lymphedema at its source.
Duracyte is advancing a novel biohybrid platform that turns implantable devices into living drug factories for sustained delivery of biologic therapies
Why Build With RBL Ventures
More Than Capital. A Company-Building Partner
Scientific founders face a unique challenge: advancing breakthrough research while simultaneously building an organization capable of translating that science into patient impact.
RBL Ventures was created to help bridge that gap.
Our founders gain access to one of the world’s leading healthcare innovation ecosystems, experienced biotechnology operators, shared company-building infrastructure, and a network of scientific, clinical, industry, and investment partners.
By working alongside RBL Ventures, founders can remain focused on advancing the science while building companies positioned for long-term success and meaningful patient impact.
CONTACT US
